Medpace raises 2026 EPS guidance range

Medpace Holdings (MEDP) reported Q3 adjusted earnings of $4.84 per share, beating estimates by $0.40, with revenue of $716.0 million, up 8.5% YoY. Full-year 2026 revenue guidance of $2.835B-$2.855B fell below analyst consensus, causing shares to drop 1.9% in after-hours trading. The company also announced a new $1.0B stock repurchase program.

Medpace Holdings (MEDP) reported Q3 EPS of $4.84, beating estimates by $0.40, with revenue of $716M, slightly above expectations. The company provided FY 2026 guidance, with EPS and revenue estimates close to consensus. The stock is up 20.90% over the past year and has seen 8 positive EPS revisions in the last 90 days, according to Investing.com.

Medpace reported Q3 2026 revenue of $716M, beating estimates by $2.3M, with EPS of $4.84, a 9.3% beat. Adjusted EBITDA was $172.1M, an 8% beat. The company reconfirmed its full-year revenue guidance of $2.85B and raised EPS guidance to $18.15, a 3.2% beat. Operating margin improved to 23.1%, while free cash flow margin declined to 27.4%.

Medpace Holdings Inc. (MEDP) reported Q3 profit of $137.5M ($4.84 per share) and revenue of $716M. The company expects full-year revenue between $2.84B and $2.86B, according to its earnings release.

Medpace Holdings, Inc. (MEDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Contact: David Ruhe 283-227-6472 d.ruhe@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 283-227-6367 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2026 Results • Revenue of $716.0 million in the third quarter of 2026 increas

Medpace (MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and GAAP EPS of $4.84. Backlog increased to $3.17B, and the company launched a $1B buyback program. 2026 guidance was reaffirmed at $2.835B–$2.855B revenue and GAAP net income of $514M–$524M.